GlassScriptPhysician profile
Vincent K Young
NPI 1841255882
$3,830.41
in general payments reported to CMS, 2019-2025
20 companies · $766 in 2025
The $766 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $439 · 2021: $378 · 2022: $571 · 2023: $385 · 2024: $663 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $557.70 | 2019-2022 | |
| Oyster Point Pharma, INC. | $500.05 | 2022-2024 | Tyrvaya |
| Alcon Vision LLC | $399.97 | 2022-2025 | Rocklatan, Clareon, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $359.47 | 2019-2021 | |
| Abbvie INC. | $317.62 | 2019-2024 | Lumigan, Alphagan P, Vuity |
| Johnson & Johnson Surgical Vision, INC. | $314.71 | 2024-2025 | Veritas Vision System, Healon Duet Pro, Catalys System |
| Novartis Pharmaceuticals Corporation | $249.23 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $234.84 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $199.84 | 2019-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $168.79 | 2019-2021 | |
| Steris Corporation | $111.64 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $92.74 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $89.68 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $80.04 | 2024-2025 | Acthar |
| Amgen INC. | $45.46 | 2024-2025 | Tepezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $39.08 | 2023 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Omeros Corporation | $16.70 | 2019 | |
| Thea Pharma INC. | $16.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.